 | • レポートコード：MRC2Q12-19123 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、性腺機能低下症治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 性腺機能低下症治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 性腺機能低下症治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 性腺機能低下症治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの性腺機能低下症治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の性腺機能低下症治療の売上および2028年までの予測に焦点を当てています。 性腺機能低下症治療のグローバル主要企業には、Bayer AG、Abbott Laboratories、Eli Lilly and Company、Sanofi、Merck、Actavis、AbbVie、Teva Pharmaceutical Industries、Endo International、Ferring Holding S.A、IBSA Pharma、Marius Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 性腺機能低下症治療市場は、タイプとアプリケーションによって区分されます。世界の性腺機能低下症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 テストステロン置換治療、エストロゲン治療、プロゲステロン治療 【アプリケーション別セグメント】 病院薬局、小売薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 性腺機能低下症治療製品概要 - タイプ別市場（テストステロン置換治療、エストロゲン治療、プロゲステロン治療） - アプリケーション別市場（病院薬局、小売薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の性腺機能低下症治療販売量予測2017-2028 - 世界の性腺機能低下症治療売上予測2017-2028 - 性腺機能低下症治療の地域別販売量 - 性腺機能低下症治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別性腺機能低下症治療販売量 - 主要メーカー別性腺機能低下症治療売上 - 主要メーカー別性腺機能低下症治療価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（テストステロン置換治療、エストロゲン治療、プロゲステロン治療） - 性腺機能低下症治療のタイプ別販売量 - 性腺機能低下症治療のタイプ別売上 - 性腺機能低下症治療のタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売薬局） - 性腺機能低下症治療のアプリケーション別販売量 - 性腺機能低下症治療のアプリケーション別売上 - 性腺機能低下症治療のアプリケーション別価格 ・北米市場 - 北米の性腺機能低下症治療市場規模（タイプ別、アプリケーション別） - 主要国別の性腺機能低下症治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの性腺機能低下症治療市場規模（タイプ別、アプリケーション別） - 主要国別の性腺機能低下症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の性腺機能低下症治療市場規模（タイプ別、アプリケーション別） - 主要国別の性腺機能低下症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の性腺機能低下症治療市場規模（タイプ別、アプリケーション別） - 主要国別の性腺機能低下症治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの性腺機能低下症治療市場規模（タイプ別、アプリケーション別） - 主要国別の性腺機能低下症治療市場規模（トルコ、サウジアラビア） ・企業情報 Bayer AG、Abbott Laboratories、Eli Lilly and Company、Sanofi、Merck、Actavis、AbbVie、Teva Pharmaceutical Industries、Endo International、Ferring Holding S.A、IBSA Pharma、Marius Pharmaceuticals ・産業チェーン及び販売チャネル分析 - 性腺機能低下症治療の産業チェーン分析 - 性腺機能低下症治療の原材料 - 性腺機能低下症治療の生産プロセス - 性腺機能低下症治療の販売及びマーケティング - 性腺機能低下症治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 性腺機能低下症治療の産業動向 - 性腺機能低下症治療のマーケットドライバー - 性腺機能低下症治療の課題 - 性腺機能低下症治療の阻害要因 ・主な調査結果 |
hypogonadism usually is treated with testosterone replacement to return testosterone levels to normal. Testosterone can help counter the signs and symptoms of male hypogonadism, such as decreased sexual desire, decreased energy, decreased facial and body hair, and loss of muscle mass and bone density.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Hypogonadism Treatment estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Hypogonadism Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Hypogonadism Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Hypogonadism Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Hypogonadism Treatment include Bayer AG, Abbott Laboratories, Eli Lilly and Company, Sanofi, Merck, Actavis, AbbVie, Teva Pharmaceutical Industries and Endo International, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Hypogonadism Treatment companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Hypogonadism Treatment market. Further, it explains the major drivers and regional dynamics of the global Hypogonadism Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Bayer AG
Abbott Laboratories
Eli Lilly and Company
Sanofi
Merck
Actavis
AbbVie
Teva Pharmaceutical Industries
Endo International
Ferring Holding S.A
IBSA Pharma
Marius Pharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Hypogonadism Treatment Segment by Type
Testosterone Replacement Treatment
Estrogen Treatment
Progesterone Treatment
Hypogonadism Treatment Segment by Application
Hospital Pharmacies
Retail Pharmacies
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Hypogonadism Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Hypogonadism Treatment market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Hypogonadism Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Hypogonadism Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hypogonadism Treatment revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Hypogonadism Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Hypogonadism Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer AG, Abbott Laboratories, Eli Lilly and Company, Sanofi, Merck, Actavis, AbbVie, Teva Pharmaceutical Industries and Endo International, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Hypogonadism Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hypogonadism Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hypogonadism Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hypogonadism Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Testosterone Replacement Treatment
1.2.3 Estrogen Treatment
1.2.4 Progesterone Treatment
1.3 Market by Application
1.3.1 Global Hypogonadism Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hypogonadism Treatment Market Perspective (2017-2028)
2.2 Hypogonadism Treatment Growth Trends by Region
2.2.1 Hypogonadism Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Hypogonadism Treatment Historic Market Size by Region (2017-2022)
2.2.3 Hypogonadism Treatment Forecasted Market Size by Region (2023-2028)
2.3 Hypogonadism Treatment Market Dynamics
2.3.1 Hypogonadism Treatment Industry Trends
2.3.2 Hypogonadism Treatment Market Drivers
2.3.3 Hypogonadism Treatment Market Challenges
2.3.4 Hypogonadism Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hypogonadism Treatment Players by Revenue
3.1.1 Global Top Hypogonadism Treatment Players by Revenue (2017-2022)
3.1.2 Global Hypogonadism Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Hypogonadism Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hypogonadism Treatment Revenue
3.4 Global Hypogonadism Treatment Market Concentration Ratio
3.4.1 Global Hypogonadism Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hypogonadism Treatment Revenue in 2021
3.5 Hypogonadism Treatment Key Players Head office and Area Served
3.6 Key Players Hypogonadism Treatment Product Solution and Service
3.7 Date of Enter into Hypogonadism Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hypogonadism Treatment Breakdown Data by Type
4.1 Global Hypogonadism Treatment Historic Market Size by Type (2017-2022)
4.2 Global Hypogonadism Treatment Forecasted Market Size by Type (2023-2028)
5 Hypogonadism Treatment Breakdown Data by Application
5.1 Global Hypogonadism Treatment Historic Market Size by Application (2017-2022)
5.2 Global Hypogonadism Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Hypogonadism Treatment Market Size (2017-2028)
6.2 North America Hypogonadism Treatment Market Size by Type
6.2.1 North America Hypogonadism Treatment Market Size by Type (2017-2022)
6.2.2 North America Hypogonadism Treatment Market Size by Type (2023-2028)
6.2.3 North America Hypogonadism Treatment Market Share by Type (2017-2028)
6.3 North America Hypogonadism Treatment Market Size by Application
6.3.1 North America Hypogonadism Treatment Market Size by Application (2017-2022)
6.3.2 North America Hypogonadism Treatment Market Size by Application (2023-2028)
6.3.3 North America Hypogonadism Treatment Market Share by Application (2017-2028)
6.4 North America Hypogonadism Treatment Market Size by Country
6.4.1 North America Hypogonadism Treatment Market Size by Country (2017-2022)
6.4.2 North America Hypogonadism Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hypogonadism Treatment Market Size (2017-2028)
7.2 Europe Hypogonadism Treatment Market Size by Type
7.2.1 Europe Hypogonadism Treatment Market Size by Type (2017-2022)
7.2.2 Europe Hypogonadism Treatment Market Size by Type (2023-2028)
7.2.3 Europe Hypogonadism Treatment Market Share by Type (2017-2028)
7.3 Europe Hypogonadism Treatment Market Size by Application
7.3.1 Europe Hypogonadism Treatment Market Size by Application (2017-2022)
7.3.2 Europe Hypogonadism Treatment Market Size by Application (2023-2028)
7.3.3 Europe Hypogonadism Treatment Market Share by Application (2017-2028)
7.4 Europe Hypogonadism Treatment Market Size by Country
7.4.1 Europe Hypogonadism Treatment Market Size by Country (2017-2022)
7.4.2 Europe Hypogonadism Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hypogonadism Treatment Market Size (2017-2028)
8.2 Asia-Pacific Hypogonadism Treatment Market Size by Type
8.2.1 Asia-Pacific Hypogonadism Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Hypogonadism Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Hypogonadism Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Hypogonadism Treatment Market Size by Application
8.3.1 Asia-Pacific Hypogonadism Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Hypogonadism Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Hypogonadism Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Hypogonadism Treatment Market Size by Region
8.4.1 Asia-Pacific Hypogonadism Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Hypogonadism Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hypogonadism Treatment Market Size (2017-2028)
9.2 Latin America Hypogonadism Treatment Market Size by Type
9.2.1 Latin America Hypogonadism Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Hypogonadism Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Hypogonadism Treatment Market Share by Type (2017-2028)
9.3 Latin America Hypogonadism Treatment Market Size by Application
9.3.1 Latin America Hypogonadism Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Hypogonadism Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Hypogonadism Treatment Market Share by Application (2017-2028)
9.4 Latin America Hypogonadism Treatment Market Size by Country
9.4.1 Latin America Hypogonadism Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Hypogonadism Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hypogonadism Treatment Market Size (2017-2028)
10.2 Middle East & Africa Hypogonadism Treatment Market Size by Type
10.2.1 Middle East & Africa Hypogonadism Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Hypogonadism Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Hypogonadism Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Hypogonadism Treatment Market Size by Application
10.3.1 Middle East & Africa Hypogonadism Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Hypogonadism Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Hypogonadism Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Hypogonadism Treatment Market Size by Country
10.4.1 Middle East & Africa Hypogonadism Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Hypogonadism Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Details
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Hypogonadism Treatment Introduction
11.1.4 Bayer AG Revenue in Hypogonadism Treatment Business (2017-2022)
11.1.5 Bayer AG Recent Developments
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Hypogonadism Treatment Introduction
11.2.4 Abbott Laboratories Revenue in Hypogonadism Treatment Business (2017-2022)
11.2.5 Abbott Laboratories Recent Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Details
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Hypogonadism Treatment Introduction
11.3.4 Eli Lilly and Company Revenue in Hypogonadism Treatment Business (2017-2022)
11.3.5 Eli Lilly and Company Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Hypogonadism Treatment Introduction
11.4.4 Sanofi Revenue in Hypogonadism Treatment Business (2017-2022)
11.4.5 Sanofi Recent Developments
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Hypogonadism Treatment Introduction
11.5.4 Merck Revenue in Hypogonadism Treatment Business (2017-2022)
11.5.5 Merck Recent Developments
11.6 Actavis
11.6.1 Actavis Company Details
11.6.2 Actavis Business Overview
11.6.3 Actavis Hypogonadism Treatment Introduction
11.6.4 Actavis Revenue in Hypogonadism Treatment Business (2017-2022)
11.6.5 Actavis Recent Developments
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Hypogonadism Treatment Introduction
11.7.4 AbbVie Revenue in Hypogonadism Treatment Business (2017-2022)
11.7.5 AbbVie Recent Developments
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Hypogonadism Treatment Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Hypogonadism Treatment Business (2017-2022)
11.8.5 Teva Pharmaceutical Industries Recent Developments
11.9 Endo International
11.9.1 Endo International Company Details
11.9.2 Endo International Business Overview
11.9.3 Endo International Hypogonadism Treatment Introduction
11.9.4 Endo International Revenue in Hypogonadism Treatment Business (2017-2022)
11.9.5 Endo International Recent Developments
11.10 Ferring Holding S.A
11.10.1 Ferring Holding S.A Company Details
11.10.2 Ferring Holding S.A Business Overview
11.10.3 Ferring Holding S.A Hypogonadism Treatment Introduction
11.10.4 Ferring Holding S.A Revenue in Hypogonadism Treatment Business (2017-2022)
11.10.5 Ferring Holding S.A Recent Developments
11.11 IBSA Pharma
11.11.1 IBSA Pharma Company Details
11.11.2 IBSA Pharma Business Overview
11.11.3 IBSA Pharma Hypogonadism Treatment Introduction
11.11.4 IBSA Pharma Revenue in Hypogonadism Treatment Business (2017-2022)
11.11.5 IBSA Pharma Recent Developments
11.12 Marius Pharmaceuticals
11.12.1 Marius Pharmaceuticals Company Details
11.12.2 Marius Pharmaceuticals Business Overview
11.12.3 Marius Pharmaceuticals Hypogonadism Treatment Introduction
11.12.4 Marius Pharmaceuticals Revenue in Hypogonadism Treatment Business (2017-2022)
11.12.5 Marius Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer